Healing the bowel wall in Crohn's disease with vedolizumab
Treatments studied
Part of Digestive system clinical trials.
This study tests whether a medicine called vedolizumab can help heal all layers of the bowel wall in Crohn's disease. It uses a special ultrasound to see inside the bowel, aiming for deeper healing than usual.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- You have moderately to severe active Crohn's disease (as determined by your doctor)
- You have either never taken a biologic or small molecule drug for Crohn's, or you have taken no more than 1 in the last 5 years
- You have not taken vedolizumab, etrolizumab, or natalizumab before
- You do not have a narrowed bowel that can't be scoped or a large abscess (pus pocket) in your belly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a personalized dosing method (using your own drug levels) can help people with Crohn's or ulcerative colitis maintain better control with vedolizumab or ustekinumab. It aims to see if adjusting doses based on your individual needs leads to fewer flare-ups and better outcomes.
This trial tests combining two medicines, vedolizumab and upadacitinib, to see if they work better together than vedolizumab alone for people with moderate to severe Crohn's disease that hasn't responded well to other treatments.
This Phase 3 study tests whether vedolizumab can better control moderate-to-severe Crohn’s disease in adults whose symptoms haven’t improved enough with other treatments. You’d need to meet specific symptom scores, recent colonoscopy findings, and safety checks (including infections and vaccination status).
This study tests the drug vedolizumab in adults with moderate to severe ulcerative colitis or Crohn's disease. It aims to see how well the medicine works in a community (non-hospital) setting.
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
Hear when a new Moderately to Severely Active Crohns Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.